BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Liquidia begins testing flu vaccine
News | 10. 06. 2010
Liquidia Technologies
Liquidia Technologies has started early clinical testing of its first vaccine developed using nanotechnology.
